C4 Therapeutics/ US12529R1077 /
2024-04-30 9:59:56 PM | Chg. -0.01 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
6.30USD | -0.16% | 17,182 Turnover: 108,027.49 |
-Bid Size: - | -Ask Size: - | 6.38 | 6.16 |
GlobeNewswire
04-08
C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single...
GlobeNewswire
03-05
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degra...
GlobeNewswire
03-04
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
02-22
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business High...
GlobeNewswire
01-09
C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted ...
GlobeNewswire
01-08
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of t...
GlobeNewswire
01-04
C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals
GlobeNewswire
2023-12-12
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple M...
GlobeNewswire
2023-12-12
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degr...
GlobeNewswire
2023-11-28
C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Re...
GlobeNewswire
2023-11-20
C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment
GlobeNewswire
2023-11-01
C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
GlobeNewswire
2023-10-11
C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC™ Deg...
GlobeNewswire
2022-03-09
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue S...
GlobeNewswire
2022-03-08
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 202...
GlobeNewswire
2022-02-24
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
GlobeNewswire
2022-01-10
C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio
GlobeNewswire
2022-01-03
C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference